Irinotecan for Cancer of Stomach
This study is evaluating whether a combination of two drugs may help treat gastric and gastroesophageal junction cancer.
See full descriptionAbout the trial for Cancer of Stomach
Treatment Groups
This trial involves 2 different treatments. Irinotecan is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Irinotecan will improve 1 primary outcome, 4 secondary outcomes, and 6 other outcomes in patients with Cancer of Stomach. Measurement will happen over the course of From when patients achieve their best response (complete response [CR] or partial response [PR]) to when they progress or die for any reason, assessed up to 1 year.
Patient Q & A Section
How many people get cancer of stomach a year in the United States?
Gastric and [esophageal cancer](https://www.withpower.com/clinical-trials/esophageal-cancer) make up 0.1-0.5% of all cancer cases in the United States. Each year, 635–715,000 Americans are diagnosed with cancer of the stomach, esophagus, or oesophageal. About 400,000 of these people will have a good chance of survival if they receive the best treatment available. Most stomach cancer treatment is performed at specialist hospitals.
What are the signs of cancer of stomach?
Signs of cancer of stomach include chronic unexplained weight loss, indigestion, abdominal pain, and constipation. If the pain is localized in the upper abdomen then malignancy is more likely. If no signs of malignancy are present, it is not necessary to perform barium enema or CT scan. If the patient has non-specific abdominal pain and weight loss, then CT scan or endoscopy should be undertaken. If the pain is localized in the lower abdomen, barium enema or CT is sufficient. If the pain is not localized, then the patient should be referred to an esophageal cancer center.
What is cancer of stomach?
Cancer of stomach or oesophagus is a serious, malignant disease that spreads rapidly and can kill its victims within two to four years. The prognosis is worse for patients with undifferentiated or poorly differentiated tumors or when the disease has metastasized, and even worse when the tumors have a high malignant potential (high grade tumor) and they have had distant metastasis.
What causes cancer of stomach?
A variety of factors may play a role in cancer development, but the precise causes remain uncertain. What has been known so far about stomach cancers and smoking? Tobacco and alcohol intake increase the risk. Poor diet, obesity, infections and cancers of the colon, bladder, cervix, oesophagus, pancreas, stomach and liver may also increase risk. Smoking, drinking tea, wine and cola beverages may protect smokers and drinkers. Diet may be protective for some groups. Poor diet and excessive drinking may also be related to colorectal cancer in people with ulcerative colitis. Obesity and alcoholism may be risk-factors for breast cancer.
What are common treatments for cancer of stomach?
Currently, few therapeutic options are available for the treatment of GC, but new targeted treatments are being developed that may have greater efficacy and tolerability than current antitumor treatments.
How serious can cancer of stomach be?
In general, cancer of stomach is rare in patients under 50 years of age, though its prevalence increases significantly in the 80+ age group. The most common form of cancer of stomach is adenocarcinoma (40%). Risk factors for adenocarcinoma of stomach are smoking, obesity, and diabetes mellitus. Cancer of stomach can spread throughout the body. Patients with [adenocarcinoma of stomach that has metastasized at the time of diagnosis] often have more than one organ at which metastatic disease is present.
Have there been any new discoveries for treating cancer of stomach?
There were recent discoveries in the last decade that showed that targeting cytokine production can lead to antitumor activity in stomach cancer. The mechanism that is used varies according to the origin of the tumor, but targeting cytokine-stimulated tumor production seems to be useful for achieving an antitumor effect in stomach cancer. If these findings are confirmed by future clinical trials, the cytokine inhibitors may have a future role in treating stomach cancer.
Have there been other clinical trials involving irinotecan?
The clinical trial of TAP was the first of its kind. The study has shown a very good effect, and there is a high rate of success in terms of remission and response to the treatment. However, there are no reports of other clinical studies using irinotecan. It is a pity that it was not used in the treatment of patients, but instead, its effects were studied in the research lab, to avoid any side effects.
What is the survival rate for cancer of stomach?
The present study suggests that there is a survival difference in gastric carcinoma cases based on a socio-economic status, but no such difference in cancers of other site. In addition, the rate of cure was correlated with survival; a longer survival rate was observed in gastric carcinomas where the cancer was at its early stages of onset and was localized in the mucosa.
What is the primary cause of cancer of stomach?
The present study showed that the following factors had a significance in predicting primary cause of stomach: age, gender, marital status, occupation and smoking habits. This indicates that factors other than smoking and alcohol consumption exert a significant influence on determining the primary cause of stomach cancer.
How does irinotecan work?
In addition to a high number of irinotecan molecules, the large volume of blood in a cancer patient may be a factor in irinotecan-related nephrotoxicity, and a lower intravenous dose may reduce this dose-related toxicity.